TNP 351
Latest Information Update: 03 Jan 1996
Price :
$50 *
At a glance
- Originator Takeda
- Class Antineoplastics
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer